EP2083799A1 - Nanoparticules micellaires de substances chimiques - Google Patents

Nanoparticules micellaires de substances chimiques

Info

Publication number
EP2083799A1
EP2083799A1 EP07821558A EP07821558A EP2083799A1 EP 2083799 A1 EP2083799 A1 EP 2083799A1 EP 07821558 A EP07821558 A EP 07821558A EP 07821558 A EP07821558 A EP 07821558A EP 2083799 A1 EP2083799 A1 EP 2083799A1
Authority
EP
European Patent Office
Prior art keywords
micelles
composition according
poorly soluble
peg
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07821558A
Other languages
German (de)
English (en)
Inventor
Jan P. MÖSCHWITZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Priority to EP07821558A priority Critical patent/EP2083799A1/fr
Publication of EP2083799A1 publication Critical patent/EP2083799A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • BCS class IV means the drug shows simultaneously poor solubility and low permeability
  • bioavailability of BCS class Il drugs is typically dissolution rate limited
  • Formulation of poorly water- soluble drugs for oral administration Physicochemical and physiological issues and the lipid formulation classification system, Colin W. Pouton, European Journal of Pharmaceutical Sciences 2006, 29, 278-87. That means that the bioavailability of BCS class Il drugs can be increased by improving their dissolution velocity and/or the saturation solubility c s .
  • cyclodextrines are cyclic oligomers of dextrose or dextrose derivatives, which can form a reversible, non-covalent association with poorly soluble drugs to solubilize them.
  • Lipid based systems such as emulsions, microemulsion, self-emulsifying drug delivery systems (SEDDS) or self-microemulsifying drug delivery systems (SMEDDS) are suitable for active substances which are soluble in lipids and oils. In these lipid formulations the active substance is dissolved in oils or lipids which either forms an emulsion or forms an emulsion system upon dilution with water.
  • top-down technologies involve an energy input to break down large particles to small particles.
  • mean particle sizes of the substance to be milled can be obtained in the micrometer range (e.g. jet-milling, hammer milling) or in the nanometer range (e.g. wet ball milling and high pressure homogenization) can be obtained.
  • a micronized starting material is recommended (US 5,145,684; US 5,858,410).
  • a typical drawback of these technologies is that they require enormous amounts of energy to break down the starting material.
  • Nanoparticulate structures normally tend to grow to form microparticles or microcrystals.
  • One approach to solve this problem is to immediately dry the prepared suspension, e.g. by lyphilization (Sucker, H., Hydrosole-eine Alternativef ⁇ r die parenterale für von schwer wasserl ⁇ slichen Wirkstoffen, in :M ⁇ ller, R. H., Hildebrand, G. E., (Hrsg.), Pharmazeutician Technologie : Moderne Arzneiformen, 2. Auflage, 1998, VWG, Stuttgart).
  • solid dispersion defines a system in a solid state (as opposed to a liquid or gaseous system) comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component or components.
  • a solid dispersion that is chemically and physically uniform or homogenous throughout or is made up of one phase as defined in thermodynamics can also be referred as solid solution (e.g. WO97/044014).
  • the solid matrix can be either crystalline or amorphous.
  • the drug can be dispersed molecularly or exist in amorphous particles (clusters) as well as crystalline particles (solid dispersion).
  • amorphous particles clusters
  • solid dispersion examples of such a solid dispersion are the tebufelone formulation described in US 5,281 ,420 and the bioactive peptide formulation described in WO 2005/053727.
  • Solid dispersions can be prepared using various methods, e.g. the fusion method, the hot-melt extrusion, the solvent evaporation method or the supercritical fluid method (DJ. van Drooge “Combining the Incompatible", Rijksuniversiteit Groningen, PhD-Thesis 2006).
  • Solid dispersions or solid solutions can comprise surfactants or other excipients to enhance the dissolution or to stabilize the drug.
  • Several techniques for the production of solid dispersions are discussed in US Patent Application 20050266088A1. This application also discloses a process to produce a sugar glass of a lipophilic compound where the lipophilic compound is dissolved in a co-solvent, preferably a CrC ⁇ alcohol.
  • the preferred solvent has a high vapor pressure and a high melting point.
  • the use of the suggested high vapor pressure, flammable co-solvents may cause difficulties on large scale production, especially when spray-drying is applied as drying technique.
  • the oxygen content in the drying air has to be reduced.
  • the lipophilic compound is not sufficiently stabilized in the aqueous co-solvent system and tend to precipitate out. For that reason a fast processing is suggested in order to avoid the occurrence of "clouding".
  • LFCS lipid formulation classification system
  • these surfactant-co- solvent mixtures are filled into soft gelatin capsules or sealed hard-gelatin capsules.
  • the drug When administered orally the drug is released after the dissolution of the capsule shell. Since the drug is already dissolved in the carrier, it can be absorbed quickly (Liquid- Filled and Seal Hard Gelatine Capsule Technologies, Ewart T. Cole, in: Modified- Release Drug Delivery Technology, eds. MJ. Rathbon, J. Hadgraft, M. S. Roberts, Marcel Dekker, Basel, 2003).
  • the present invention relates to a thermostable composition having improved dissolution behavior, the composition comprising nanosized micelles, wherein the micelles comprise a poorly soluble compound.
  • the pharmaceutical composition of the present invention comprises nanosized micelles, wherein the micelles comprise a surfactant or a surfactant-co-solvent mixture containing a poorly soluble chemical substance, such as a drug poorly soluble drug, wherein the micelles are embedded in a water-soluble matrix of a water soluble carrier, such as a pharmaceutically acceptable carrier.
  • Another aspect of the invention relates to the preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising preparing an aqueous micellar solution comprising a poorly soluble compound, an auxiliary material or a mixture of auxiliary materials and a water soluble matrix and drying the micellar solution to embed these micelles in the water- soluble matrix of the carrier to obtain a thermostable composition.
  • Micelles containing the poorly soluble compound are produced using one or more surfactants and optionally one ore more co-solvents.
  • Figure 1 is a diagram of the general process of preparing a composition, for example a pharmaceutical composition, according to the present invention.
  • Figure 2 is a graph that illustrates the plasma concentrations of COMPOUND 1 obtained after administering four different formulations, including the formulation according to the present invention, to male beagle dogs.
  • thermostable solid composition comprising nanosized micelles, wherein said micelles comprise a poorly soluble chemical substance dissolved in an auxiliary material, and wherein said micelles are embedded in a water soluble carrier.
  • thermostable solid pharmaceutical composition comprising nanosized micelles, wherein said micelles comprise a poorly soluble biologically active substance dissolved in an auxiliary material, and wherein said micelles are embedded in a matrix of a water soluble pharmaceutically acceptable carrier.
  • thermostable means that the formulation remains a free flowing stable powder when heated above the melting point of the main auxiliary material. This means that the formulation remains physically stable when heated 5°, 10°, 20°, 30° ,40° or 5O 0 C above the melting point of the main auxiliary material.
  • Vitamin E TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) has a melting point of 36 0 C (Reference: Eastman, Material Safety Data Sheet of Vit E TPGS NF Grade).
  • a person skilled in the art would assume that if Vitamin E TPGS is the main component of a formulation, this formulation would show at least experience partial melting when exposed to a temperature much above 36 0 C, for instance 8O 0 C.
  • Vitamin E TPGS is used as an auxiliary material in the present invention
  • the Vitamin E TPGSforms micelles and the micelles of Vitamin E TPGS (and an active substance) are embedded in a water-soluble matrix material, which has a melting point above 36 0 C
  • the resulting powder will not show a major change in powder morphology and flowability. It remains a stable, free-flowing powder even if exposed to temperatures 5°, 10°, 20°, 30° ,40° or 5O 0 C above the melting point of the main auxiliary material, Vitamin E TPGS.
  • biologically active substance pharmaceutically active substance, drug, active compound, active ingredient are used interchangeably to refer to a chemical substance or chemical compound which, when administered to a human or animal being, induces a pharmacological effect.
  • poorly soluble compound in the framework of the present invention means a compound which has a solubility in water at 37 0 C of less than 33 g/L.
  • poorly soluble compound is used to describe a compound that has a solubility of less than 33 g/L under the conditions, in particular the pH, at the site in vivo (e.g. in the stomach, in the intestines, subcutaneous) where the compound is intended to become available to the body (in particular where the compound is dissolved to be absorbed by the body).
  • a poorly soluble compound intended to dissolve in the stomach has a solubility below 33 g/l in gastric fluid (pH of about 1 -3) and a poorly soluble compound to be dissolved in the intestines has a solubility below 33 g/l in intestinal fluid (typically up to about pH 7.4).
  • the present invention is especially useful for even more poorly soluble compounds, such as compounds having a solubility in the gastro-intestinal fluid of below 10 g/L, 4 g/L, 1 g/L, 100 mg/L, 40 mg/L, 10 mg/L, 4 mg/L,
  • the poorly soluble compound that can be processed according to this invention can be liquid, semi-solid, solid amorphous, liquid crystalline or solid crystalline.
  • the poorly soluble compound to be processed according to this invention is preferably a pharmaceuticaly active agent and can be chosen from analgesics, antiarrhythmic agents, anti-asthma agents, anti-biotic agents, anti-helminthics, anti- inflammatory agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-erectile dysfunction agents, anti-fungal agents, anti-gout agents, antihypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, antineoplastic agents, anti-obesity agents, anti-parkinsonian agents, anti-protozoal agents, anti-thyroid agents, anti-tussives, anxiolytics, beta-blockers, hypnotics, immunosuppressants, neuroleptics, cannabinoid receptor agonists and antagonists, cardie inotropic agents, cell adhesion inhibitors, cortic
  • poorly soluble compounds are poorly soluble cannabinoid agonists, inverse agonists and antagonists. Some examples of these compounds are the compounds disclosed in WO01/70700, WO02/076949, WO03/026647, WO03/026648, WO03/027076, WO2005/074920, WO 2005/080345, WO 2005/118553 and WO2006/087355 such as (4S)-3-(4-chlorophenyl)-4,5-dihydro-N-methyl-4-phenyl-N'-(1- piperidinyl-sulfonyl)-1 H-pyrazole-1-carboximidamide described in WO 03/026648 and (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methyl-4-phenyl-1 H- pyrazole-1-carboximidamide
  • the poorly soluble compound in the composition of the present invention preferably has a log P lower than 10, more preferably lower than 5 and even more preferably lower than 2.5 and may be present in an amount from 0.05% w/w to at least 50% w/w, preferably in an amount between 0.05 and 10% or between 0.05% and 5% or between 0.05% and 1 % of the total weight of the composition.
  • auxiliary material in the framework of the present invention is a material that enables the formation of micelles when it is brought in contact with water or a material that has a positive effect on the stability of micelles when they have been formed, such as a surfactant, a co-solvent or a mixture of a surfactant and a co-solvent.
  • micelle in the framework of the present invention means an association of surfactant molecules which in aqueous solutions are above the Krafft point and the critical micellization concentration (Ref. R ⁇ mpp Online Dictionary).
  • surfactants in solution often form association colloids. That is, they tend to form aggregates of colloidal dimensions, which exist in equilibrium with the molecules or ions from which they are formed. Such aggregates are termed micelles.
  • Krafft point means the temperature (more precisely, narrow temperature range) above which the solubility of a surfactant in water rises sharply. At this temperature the solubility of the surfactant becomes equal to the critical micelle concentration.
  • the micelles in the composition according to the present invention have a mean size smaller than 1000 nm, preferably smaller than 500 nm or smaller than 200 nm or smaller than 100 nm.
  • mean size in the framework of the present invention refers to an effective average diameter determined by dynamic light scattering methods (e.g., photocorrelation spectroscopy (PCS), laser diffraction (LD), low-angle laser light scattering (LALLS), medium-angle laser light scattering (MALLS), light obscuration methods (Coulter method, for example), rheology, or microscopy (light or electron) within the ranges set forth above).
  • PCS photocorrelation spectroscopy
  • LD laser diffraction
  • LALLS low-angle laser light scattering
  • MALLS medium-angle laser light scattering
  • light obscuration methods Coulter method, for example
  • rheology light or electron
  • composition according to the present invention may comprise at least 10% of a surfactant or at least 30%, or at least 50% and may comprise up to 99.95% of surfactant.
  • the composition contains also one or more co-solvents and/or one or more cosurfactants.
  • the surfactants and the optional cosurfactants that can be used are listed in M. M. Rieger, "Surfactants", Chapter 8 in Pharmaceutical Dosage Forms, Marcel Dekker Inc., (1993), p. 285-359.
  • Preferred surfactants are surfactants with a HLB value larger than 8.
  • Most preferred surfactants are selected from the group consisting of polyoxyethylen stearates (such as Solutol®), Polyoxyethylene sorbitan fatty acid esters (such as Tween®), Polyoxyethylen Castor Oil Derivatives (such as Chremophor®), Vitamin E TPGS, nonionic polyoxyethylene-polyoxypropylene block co-polymers (such as Poloxamer®), water-soluble long chain organic phosphate esters (such as Arlatone®), inulin lauryl carbamate (such as lnutec SP1®).
  • polyoxyethylen stearates such as Solutol®
  • Polyoxyethylene sorbitan fatty acid esters such as Tween®
  • Polyoxyethylen Castor Oil Derivatives such as Chremophor®
  • Vitamin E TPGS nonionic polyoxyethylene-polyoxypropylene block co-polymers
  • Poloxamer® water-soluble long
  • the optional co-solvent used is preferably a pharmaceutically acceptable non-volatile co-solvent, which is a substance having a vapor pressure lower than 0.50 mm Hg at 25 0 C.
  • the pharmaceutical composition is only related to solubilizing mixtures of type IV of the lipid formulation classification system (LFCS), defined by Pouton (see paragraph [0012]) as oil-free formulations based on surfactants and co-solvents and therefore oils are specifically excluded as co-solvents in the present invention.
  • LFCS lipid formulation classification system
  • LFCS Type I formulations Non-disperging; requireg digestion
  • LFCS Type Il formulations SEDDS without water-soluble components
  • LFCS Type IMA formulations SEDDS/SMEDDS with water soluble components
  • LFCS Type NIB formulations SMEDDS with water soluble components and low oil content
  • nonvolatile co-solvent examples include, without limitation, alkylene glycols such as, polyethylene glycol (PEG), propylene glycol, diethylene glycol monoethyl ether, glyceryl triacetate, benzyl alcohol, polyhydric alcohols, e.g., mannitol, sorbitol and xylitol; polyoxyethylenes; linear polyols, e.g., ethylene glycol, 1 ,6-hexanediol, neopentyl glycol and methoxypolyethylene glycol; and mixtures thereof.
  • alkylene glycols such as, polyethylene glycol (PEG), propylene glycol, diethylene glycol monoethyl ether, glyceryl triacetate, benzyl alcohol, polyhydric alcohols, e.g., mannitol, sorbitol and xylitol; polyoxyethylenes; linear polyols, e.g.
  • PEG is a polymer of ethylene oxide that conforms generally to the formula (HOCH 2 CH 2 ) n OH wherein n is the number of units which is also the number defining the average molecular weight (m.w.) of the polymer.
  • liquid PEG refers to PEG having a molecular weight (m.w.) such that the substance is in a liquid state at room temperature and pressure.
  • m.w. molecular weight
  • Particularly useful are PEG 400 (m.w. from about 380-420 Daltons), PEG 600 (m.w. from about 570-630 Daltons), and mixtures thereof.
  • PEGs are commercially- available from Dow Chemical (Danbury, Conn.) under the CARBOWAX SENTRY line of products.
  • solid PEG refers to PEG having a molecular weight such that the substance is in a solid state at room temperature and pressure.
  • PEG having an average m.w. ranging between 900 and 20,000 Daltons is a solid PEG.
  • Particularly useful solid PEGs are those having a m.w. between 3,350 Daltons (m.w. from about 3015 to about 3685 Daltons) and 8,000 Daltons (m.w. from about 7,000 to 9,000 Daltons).
  • Especially useful as a solid PEG are PEG 3350, PEG 4000 (m.w. from about 3,600 to 4,400 Daltons), PEG 8000 and mixtures thereof.
  • the formulation comprises the co-solvent in an amount of from 0.01 % w/w to 99.95% w/w, preferably from 10.0% w/w to 90.0% w/w and most preferably from 20.0% w/w to 70.0% w/w.
  • the water soluble carrier (also indicated as matrix) can be any polymeric material that is soluble in water.
  • a matrix material can be considered being soluble in water if at least one part of the matrix material can be dissolved in 10 to 30 parts water (definition according to USP 24, page 2254).
  • the water soluble carrier should be pharmaceutically acceptable.
  • pharmaceutically acceptable carriers that are useful in the present invention are chosen from: - alkylcelluloses such as methylcellulose; hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose; hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl-methylcellulose; - carboxyalkylcelluloses such as carboxymethylcellulose; alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose;
  • carboxyalkylalkylcelluloses such as carboxymethylethylcellulose; carboxyalkylcellulose esters;
  • polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gummi arabicum, guar gummi and xanthan gummi; - polyacrylic acids and the salts thereof; polymethacrylic acids and the salts thereof, methacrylate copolymers;
  • polyvinylalcohol polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate;
  • polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide.
  • Non-enumerated polymers which are pharmaceutically acceptable and have appropriate physico-chemical properties as defined hereinbefore are equally suited as a carrier in the present invention for pharmaceutical compositions.
  • Preferred water-soluble polymers that are useful in the present invention include hydroxypropyl methylcelluloses and HPMC.
  • HPMC contains sufficient hydroxypropyl and methoxy groups to render it water-soluble.
  • HPMCs having a methoxy degree of substitution from about 0.8 to about 2.5 and a hydroxypropyl molar substitution from about 0.05 to about 3.0 are generally water soluble.
  • Methoxy degree of substitution refers to the average number of methyl ether groups present per anhydroglucose unit of the cellulose molecule.
  • Hydroxy-propyl molar substitution refers to the average number of moles of propylene oxide which have reacted with each anhydroglucose unit of the cellulose molecule.
  • Hypromellose is the United States Adopted Name for hydroxypropylmethylcellulose.
  • composition according to the present invention may include one or more other additives.
  • these additives should be pharmaceutically acceptable additives such as flavouring agents, colourants, binders, fillers, filler-binders, lubricants, disintegration aids and/or other pharmaceutically acceptable additives.
  • the preparation of a composition according to the present invention involves the preparation of an aqueous micellar solution of a poorly soluble compound followed by a drying step to embed these micelles in a water-soluble matrix of a carrier, such as a pharmaceutically acceptable carrier.
  • Micelles containing the poorly soluble compound are produced by using one or more surfactants. If desired, one ore more co-solvents can be also included.
  • the micellar solution comprising the poorly soluble compound is prepared by dissolving the poorly soluble compound in one or more surfactants.
  • Dissolving means that the poorly soluble compound is substantially mono- molecularly dispersed, i.e. at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% of the poorly soluble compound is mono-molecularly dispersed.
  • one ore more co- solvents can be added.
  • energy can be applied to enable the complete molecular distribution by heating, blending or mixing of the components.
  • the aqueous phase can contain a dissolved matrix of a carrier, such as a pharmaceutically acceptable carrier, or the water-soluble matrix of the carrier is dissolved afterwards in the micellar solution.
  • This mixture is dried to obtain a solid powder.
  • the powder can be used as it is or mixed with other excipients and processed further.
  • the composition according to the invention facilitates the absorption of poorly soluble drugs by forming micellar solutions of the drug when the composition is administered.
  • a further aspect of the invention is that the composition, e.g. the solid powder, can be easily processed into formulations, even using excipients which are known to be not compatible with hard gelatin capsules (e.g. PEG 400, Glycerol, Polyoxyl 35 Castor Oil (e.g. Cremophor EL®), Propylene Glycol, Diethylene glycol monoethyl ether (e.g. Transcutol P®), Sorbitan monooleate (e.g. Span 80®)), can be processed into powders for capsule filling.
  • excipients which are known to be not compatible with hard gelatin capsules
  • excipients e.g. PEG 400, Glycerol, Polyoxyl 35 Castor Oil (e.g. Cremophor EL®), Propylene Glycol, Diethylene glycol monoethyl ether (e
  • Freeze drying is typically not the production process used for large scale production and is normally only applied for extreme labile drugs, such as proteins. Spray drying is more convenient and better suitable for large scale production. Therefore spray-drying was tested as the drying method for the micellar solutions according to the invention and was found to be very suitable for the production. Since no flammable co- solvents with high vapor pressure are used the production of the spray dried powders can be performed on standard equipment without special protection against explosion. Furthermore the micellar solutions are stable for hours, in some cases even for days, without precipitation of the drug. The dissolution testing has shown, that approximately the same dissolution velocity can be obtained, irrespectively of the utilized drying method.
  • the inventive method is not limited to surfactant-co-solvent mixtures.
  • a pharmaceutical composition according to the present invention may be processed further into any solid dosage form for any route of administration.
  • Dosage forms of particular interest are granules, compressed (immediate release) tablets for oral delivery, sublingual or buccal tablets and powder or granular filled hard gelatin capsules or sachets.
  • a tablet is a common type of solid dosage form used to administer a pharmaceutical composition.
  • liquid or semisolid formulations which contain the poorly soluble drug in solubilized (i.e. dissolved) form.
  • One procedure that has been used to produce such tablets is the adsorption of liquid drugs or drug solution onto selected carriers (Spireas et al., Powdered solution technology: principles and mechanisms, Pharm. Res. 9 No. 10, 1351- 1358, 1992).
  • a typical drawback of the resulting powder is its poor flowability and compressability. It is an objective of this invention to provide a solution for this problem.
  • the powders produced according to the present invention in particular the powders produced by spray drying, show very good flowability.
  • the dry powder can be mixed in dry state with pharmaceutical excipients.
  • the resulting powder mixtures can be filled directly into capsules, however even a compression to tablets is possible.
  • the tablets obtained have shown a very fast drug release, the release velocity was comparable to that of the capsule formulation of the similar composed powder.
  • granulated fumed-silica e.g. AEROPERL® 300
  • a very fast disintegration of the tablets and therefore a good drug release was obtained.
  • Tablets produced according to the present invention have shown a much better drug release then with those produced by standard approaches (e.g, melt-extrusion or liquid filled capsules).
  • liquid-filled capsules is another state of the art technology to provide a dosage form that can be used for administering a pharmaceutical composition.
  • a molten drug-surfactant-co-solvent (PEG 4000) mixture was filled into hard gelatin capsules, solidified and submitted for drug release studies it appeared that the molten drug-surfactant-co-solvent mixture was compatible with the capsule shell.
  • these capsules have also shown a relatively slow drug release. After 20 minutes only 52 % of the drug was released.
  • drug release from a formulation according to the present invention which has a release of more than 80%, is superior as compared to drug release from conventional liquid-filled capsules known in the art.
  • freeze drying is not typically used for large scale production it can be also used according to the present invention for the production of powders which can be compressed into tablets. Freeze drying may be used when only a limited amount of drug is available (e.g. in early development stages) and tablets according the present invention are desired. It was found that the freeze dried powder could be successfully compressed into tablets, even without adding any additional excipient. These "unformulated" tablets have shown a promising drug release of approx. 62% after 20 minutes which can certainly be raised by adding standard tabletting excipients.
  • the present invention also relates to a process for preparing the composition of the present invention.
  • the invention in a first aspect relates to a process for preparing a solid pharmaceutical composition as described above, comprising the following steps: a) dissolving a poorly soluble active substance in an auxiliary material or a mixture of auxiliary materials; b) optionally adding one or more additional auxiliary materials to the solution obtained in a); c) mixing the solution obtained in a) or b) with water to form nanosized micelles; d) dissolving a matrix forming material in the mixture obtained in c); and e) drying the mixture obtained in d) to obtain a solid pharmaceutical composition, wherein the micelles are embedded in the matrix forming material.
  • the invention relates to a process for preparing a solid pharmaceutical composition as described above, comprising the following steps: a) dissolving a poorly soluble active substance in an auxiliary material or a mixture of auxiliary materials; b) optionally adding one or more additional auxiliary materials to the solution obtained in a); c) dissolving a matrix forming material in water; d) mixing of the solution obtained in a) or b) with the solution obtained in c) to form nanosized micelles; and e) drying the mixture obtained in (d) to obtain a solid pharmaceutical composition, wherein the micelles are embedded in the matrix forming material.
  • the invention relates to a process for preparing a solid pharmaceutical composition as described above, comprising the following steps: a) dissolving a poorly soluble active substance in either an auxiliary material or a mixture of auxiliary materials; b) dissolving the solution obtained in a) in water to form nanosized micelles; c) optionally adding one or more additional auxiliary materials to the solution obtained in b); d) dissolving a matrix forming material in the solution obtained in b) or c); and e) drying the mixture obtained in d) to obtain a solid pharmaceutical composition, wherein the micelles are embedded in the matrix forming material.
  • the invention in another aspect relates to a process of preparing a solid pharmaceutical composition as described above, comprising the following steps: a) dissolving the auxiliary material or the mixture of auxiliary materials in water to form nanosized micelles; b) dissolving the poorly soluble active substance in the solution obtained in a), wherein the solution obtained contains micelles comprising the poorly soluble active substance; c) optionally adding one or more additional auxiliary materials to the solution obtained in b); and d) dissolving the matrix forming material in the solution obtained in b) or e); and e) drying the mixture obtained in d) to obtain a solid pharmaceutical composition, wherein the micelles are embedded in the matrix forming material.
  • the invention relates to a process of preparing a solid pharmaceutical composition as described above, comprising the following steps: a) dissolving the auxiliary material or the mixture of auxiliary materials in water; b) dissolving the poorly soluble active substance in the solution obtained in a); c) adding one or more additional auxiliary materials to the solution obtained in b), to form a solution containing micelles comprising the poorly soluble active substance; and d) dissolving the matrix forming material in the solution containing the micelles comprising the poorly soluble active substance obtained in c); and e) drying the mixture obtained in d) to obtain a solid pharmaceutical composition, wherein the micelles are embedded in the matrix forming material.
  • the micelles can be formed in either step a), step b), step c) or step d).
  • micelles can be formed in step a) when the auxiliary material or mixture of auxiliary materials used in step a) contains a surfactant and the surfactant is brought into contact with water in step a). In that case, the micelles do not yet contain the poorly soluble active substance and the poorly soluble active substance is included in the micelles in step b).
  • the micelles can be formed in step b) when the surfactant is brought into contact with water in step b).
  • the micelles are formed in step c) when they have not yet been formed in step a) or b).
  • the invention relates to a process for preparing a solid pharmaceutical composition as described above, comprising the following steps:
  • the drying step indicated above can be performed by freeze drying, spray drying or freeze spray drying.
  • the most preferred drying method is spray drying.
  • the powder formed by applying one of the processes described above is free- flowing and remains stable and free-flowing when heated above the melting temperature of the main auxiliary material, even when the amount of matrix forming material is very low, such as lower than 50%, even lower than 30%, even lower than 20% or even lower than 10%.
  • the micelles remain existent as in the original aqueous micellar solution, but they are now embedded in the solid matrix and thereby stabilized. Upon dissolution in water the original aqueous micellar solution is formed again (see Figure 1 ).
  • the product after drying may be further processed into granules, compressed tablets, sublingual or buccal tablets or the dried composition may be filled into capsules or sachets in the form of powder or in the form of granules with the aid of conventional methods and apparatuses.
  • thermostable solid composition of a poorly soluble active compound can be obtained with a very high bio-availability.
  • a bioavailability study (in male beagle dogs) of formulations comprising a poorly soluble compound, COMPOUND 1 (SLV330), was conducted. It was found that the relative bioavailability in male beagel dogs of the composition according to the present invention was about 6 times higher as compared with the relative bio-availability of a composition comprising micronized active compound (see Table 2 below).
  • the present invention is developed on the basis of active substances that can be used in the field of medicine, the principle can be used in other fields of technology wherein nanosized particles have an advantage, and therefore the present invention is not restricted in its use to the field of medicine
  • Example 1 Materials and Methods.
  • F00761 Materials Polyethylene glycol (e g PEG 400 and PEG 4000), Polyoxyethylensorbitanmonooleat (e g Polysorbat 80®), Macrogol-15 hydroxys tearate (e g Solutol® HS 15), anhydrous citric acid, mannitol, hydroxypropylmethylcellulose (e g HPMC E5®), d-alpha-tocopheryl polyethylene glycol 1000 (Vitamin E TPGS), sodium dodecyl sulfate (SDS), Polyvinylpolypyrrolidone (PVP-CL), Sodium Stearyl Fumarate (e g Pruv®), Microcrystalline cellulose (MCC) and granulated fumed silica (e g Aeropearl 300®) were obtained from commercial sources COMPOUND 1 (4S)-3-(4-chlorophenyl)-4,5-dihydro-N-methyl-4-phenyl-N'-(1-piperidinyl-
  • the mass spectrometer operation mode was Turbo IonSpray positive, the analytical column was a Waters Acquity BEH phenyl 1.7 urn, 100 mm x 2.1 mm (id). Concentrations of COMPOUND1 in calibration standards and QC samples were determined using a quadratic regression with the reciprocal of the concentration (1/x) as weighting. The data were collected and processed using Applied Biosystems/MDS Sciex AnalystTM software 1.4.1.
  • Example 2 Preparation of COMPOUND 1 formulation (FD PEG 400). 50 mg of the poorly soluble drug COMPOUND 1 was weighed in a glass injection vial. Afterwards 950 mg of a surfactant-co-solvent mixture containing 66.34% (w/w) PEG 400, 16.58% (w/w) Polysorbat 80, 16.58% (w/w) Solutol® HS 15 and 0.5% anhydrous citric acid (w/w) was added to this vial. After complete dissolution of the drug 4 ml of an aqueous Mannitol solution (10% w/w) was added to the vial and the contents were mixed well. Within the next 5 seconds the vial was given into a bath of liquid nitrogen to freeze the mixture rapidly. Finally, the frozen mixture was lyophilized in a lab freeze dryer (Christ Alpha 2-4, SaIm and Kipp, The Netherlands) at -80 0 C and 0.050 mbar for 48 hours. A fluffy cake was obtained.
  • a lab freeze dryer (Christ Alpha
  • a poorly soluble drug (COMPOUND 1 ) were weighed in a glass injection vial. Afterwards 950 mg of a surfactant-co-solvent mixture containing 66.34% (w/w) PEG 4000, 16.58% (w/w) Polysorbat 80, 16.58% (w/w) Solutol® HS 15 and 0.5% anhydrous citric acid (w/w) was added to this vial. This mixture was stored in an oven at 8O 0 C until the drug was completely dissolved. Afterwards 4 ml of a heated (8O 0 C) aqueous Mannitol solution (10% w/w) was added to the vial and the contents were mixed well until any solid content was dissolved.
  • a surfactant-co-solvent mixture containing 66.34% (w/w) PEG 4000, 16.58% (w/w) Polysorbat 80, 16.58% (w/w) Solutol® HS 15 and 0.5% anhydrous citric acid (w/w) was added
  • Example 4 Preparation of COMPOUND 1 formulation (SD PEG 4000).
  • the resulting solution was than spray-dried using an Mini Spray Dryer B ⁇ chi 191 (B ⁇ chi, Switzerland).
  • the airflow was 600 l/h
  • the inlet temperature was 150 0 C
  • the aspirator was set to 80%
  • the feed flow rate was about 5.5g /min
  • the outlet temperature under these conditions was about 90 0 C.
  • a free-flowable powder was obtained.
  • Example 5 Preparation of COMPOUND 1 formulation (SD TPGS).
  • micellar solution was processed according to the present invention.
  • Example 6 Particle size COMPOUND 1 formulation (before and after SD PEG 4000).
  • the particle size of the drug micelles was determined before and after spray drying using a laser d iff racto meter Coulter LS 13 320 (Beckman Coulter, Fullerton, CA, USA) equipped with a Coulter Aqueous Liquid Module.
  • the real refractive index for the fluid was set at 1.33 (water).
  • the real refractive index was set at 1.46 and the imaginary refractive index at 0.01. 50 mg of a poorly soluble drug (COMPOUND 1 ) was weighed in a glass injection vial.
  • micellar solution determined as volume weighted diameter d 95% by laser diffraction was 254 nm.
  • Example 7 Tabletting of the FD Powder of COMPOUND 1.
  • Example 3 The powder resulting from Example 3 was compressed to a bifacial tablet with a diameter of 12.5 mm by using an experimental hydraulic press and a compaction pressure of 100 bars applied for 40 sec.
  • Example 8 Tabletting of the SD Powder of COMPOUND 1.
  • 325 mg of the powder produced according to Example 4 was mixed with 325 mg granulated hydrophilic fumed silica (AEROPERL® 300/30, Degussa AG, Germany) and 125 mg polyvinylpyrrolidone (Kollidon® CL, BASF, Germany). Then the mixture was compressed to a bifacial tablet with a diameter of 12.5 mm by using an experimental hydraulic press and a compaction pressure of 40 bars applied for 2 sec.
  • AEROPERL® 300/30 325 mg granulated hydrophilic fumed silica
  • Kollidon® CL polyvinylpyrrolidone
  • Example 9 Release Profile PEG 400 capsules (FD) of COMPOUND 1.
  • the powder produced according to Example 2 was filled into hard gelatine capsules.
  • the drug content in one capsule was 25mg.
  • the dissolution test was performed according USP II.
  • the vessels were filled with 900 ml. of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C.
  • the paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes. Samples of 10 ml. were taken after 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes filtered through a 0.22 ⁇ m filter.
  • Example 3 The powder resulting from Example 3 was filled into hard gelatine capsules.
  • the drug content in one capsule was 25mg.
  • the dissolution test was performed according USP II.
  • the vessels were filled with 900 ml. of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C.
  • the paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes. Samples of
  • 650 mg of the powder produced according Example 4 was filled into hard gelatine capsules.
  • the drug content in one capsule was 25mg.
  • the dissolution test was performed according USP II.
  • the vessels were filled with 900 ml. of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C.
  • the paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes.
  • Samples of 10 ml. were taken after 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes filtered through a 0.22 ⁇ m filter. All experiments were performed in triplicate and the mean of these three experiments ⁇ the covariance was plotted as function of the time.
  • Drug content in the samples was determined with HPLC. After 20 min approx. 85% of the drug was released.
  • the drug release from tablets produced according to Example 8 was tested.
  • the drug content per tablet was 25 mg.
  • the dissolution test was performed according USP II.
  • the vessels were filled with 900 mL of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C.
  • the paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes.
  • Samples of 10 mL were taken after 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes, filtered through a 0.22 ⁇ m filter. All experiments were performed in triplicate and the mean of these three experiments ⁇ the covariance was plotted as function of the time.
  • Drug content in the samples was determined with HPLC. After 20 min approx. 82 % of the drug was released.
  • Example 13 PEG 4000 tablets of COMPOUND 1 without spray-drying.
  • a comparative formulation was prepared, in order to compare the release profile of formulations produced according the invention with those of a standard approach (e.g. melt-extrusion)other formulations have been produced. Therefore 150 mg of a poorly soluble drug (COMPOUND 1 ) was weighed in a glass injection vial. Afterwards 2850 mg of a heated (80 0 C) surfactant-co-solvent mixture containing 66.67% (w/w) PEG 4000, 16.67% (w/w) Polysorbat 80, and 16.67% (w/w) Solutol® HS 15 was added to this vial.
  • a heated (80 0 C) surfactant-co-solvent mixture containing 66.67% (w/w) PEG 4000, 16.67% (w/w) Polysorbat 80, and 16.67% (w/w) Solutol® HS 15 was added to this vial.
  • Example 14 Dissolution of PEG 4000 COMPOUND 1 tablets without spray- drying.
  • Example 15 Liquid filled capsules of COMPOUND 1 based on PEG 4000.
  • a comparative formulation was prepared in order to compare the release profile of formulations produced according the invention with those of a standard approach (e.g. liquid-filled capsules) other samples have been produced. Therefore 150 mg of a poorly soluble drug (COMPOUND 1 ) was weighed in a glass injection vial. Afterwards 2850 mg of a heated (80 0 C) surfactant-co-solvent mixture containing 66.67% (w/w) PEG 4000, 16.67% (w/w) Polysorbat 80, and 16.67% (w/w) Solutol® HS 15 were added to this vial. This mixture was stored in an oven at 80 0 C until the drug was completely dissolved. The resulting solution was filled into hard gelatine capsules (Licaps size 0, Capsugel, Belgium) and cooled down to 25 ° C for solidification. Every capsule was filled with 500 mg molten mass (containing 25 mg COMPOUND 1 ).
  • a heated (80 0 C) surfactant-co-solvent mixture containing 6
  • Example 16 Dissolution of Liquid filled COMPOUND 1 capsules based on PEG 4000. The drug release from capsules produced according to Example 15 was tested. The drug content per tablet was 25 mg. The dissolution test was performed according USP II. The vessels were filled with 900 ml. of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C. The paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes. Samples of 10 ml. were taken after 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes filtered through a 0.22 ⁇ m filter. All experiments were performed in triplicate and the mean of these three experiments ⁇ the covariance was plotted as function of the time. Drug content in the samples was determined with HPLC. After 20 min approx. 52 % of the drug was released.
  • Example 17 Preparation of COMPOUND 2 formulation (SD). 250 mg of the poorly soluble drug COMPOUND 2 was weighed in a glass flask. Afterwards 9.75 g of a surfactant-co-solvent mixture containing 66.34% (w/w) PEG 4000, 16.58% (w/w) Polysorbat 80, 16.58% (w/w) Vitamin E TPGS and 0.5% anhydrous citric acid (w/w) was added to this flask. This mixture was stored in an oven at 80 0 C until the drug was completely dissolved. 1g of this molten solution was mixed with 100 ml of an aqueous hydroxypropyl methylcellulose solution (HPMC Grad E5, 0.016% w/w).
  • HPMC Grad E5 0.016% w/w
  • the resulting solution was than spray-dried using a Mini Spray Dryer B ⁇ chi 191 (B ⁇ chi, Switzerland).
  • the airflow was 600 l/h
  • the inlet temperature was 150°C
  • the aspirator was set to 80%
  • the feed flow rate was about 5.5g /min
  • the outlet temperature under these conditions was about 90 0 C. This process was repeated until the complete drug- surfactant-co-solvent mixture was processed. A free-flowable powder was obtained.
  • Example 18 Tabletting of the SD Powder of COMPOUND 2.
  • 650 mg powder produced according to example 17 was mixed with 450 mg granulated hydrophilic fumed silica (AEROPERL® 300/30, Degussa AG, Germany) and 200 mg polyvinylpyrrolidone (Kollidon® CL, BASF, Germany). The, the mixture was compressed to a bifacial tablet with a diameter of 12.5 mm by using an experimental hydraulic press and a compaction pressure of 40 bars applied for 2 sec.
  • AEROPERL® 300/30 granulated hydrophilic fumed silica
  • Kollidon® CL polyvinylpyrrolidone
  • the drug release from tablets produced according to Example 18 was tested.
  • the drug content per tablet was 12.5 mg.
  • the dissolution test was performed according USP II.
  • the vessels were filled with 900 ml. of 0.1 M HCI containing 0.5 % w/v sodium dodecyl sulfate at 37.5 ° C.
  • the paddle speed was set at 50 rpm during the first 90 minutes, after which the paddle speed was increased to 150 rpm for another 30 minutes.
  • Samples of 10 ml. were taken after 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes filtered through a 0.22 ⁇ m filter. All experiments were performed in triplicate and the mean of these three experiments ⁇ the covariance was plotted as function of the time.
  • Drug content in the samples was determined with HPLC. After 20 min approx. 92 % of the drug was released.
  • Example 20 Preparation of COMPOUND 3 formulation (SD TPGS). 0.2 g of a poorly soluble drug (COMPOUND 3) was weighed in a flask. Afterwards 1.8 g of a heated (80 0 C) Vitamin E TPGS containing 0.5% (w/w) anhydrous citric acid was added to this flask. This mixture was stored in an oven at 80 0 C until the drug was completely dissolved. 2g of this molten solution was mixed with 100 ml of an aqueous hydroxypropylmethylcellulose solution (HPMC Grad E5, 0.6% w/w). The resulting solution was then spray-dried using an Mini Spray Dryer B ⁇ chi 191 (B ⁇ chi, Switzerland).
  • micellar solution was processed according to the present invention.
  • Example 21 Scale up experiment of COMPOUND 1 formulation (SD TPGS).
  • micellar solution 100.0 g of a poorly soluble drug (COMPOUND 1 ) was weighed in a flask. Afterwards 1900.0 g of a heated (80 0 C) Vitamin E TPGS containing 0.5% (w/w) anhydrous citric acid was added to this flask. This mixture was stored in an oven at 80 0 C and stirred until the drug was completely dissolved. 2kg of this molten solution (2000.0 g) was mixed with 18.0 L of an aqueous hydroxypropylmethylcellulose solution (HPMC Grad E5, 3.33% w/w). The resulting micellar solution was than spray-dried using a spray dryer Niro Atomizer Mobile Minor (Niro Inc.).
  • the inlet temperature was 250 0 C
  • the feed flow rate was about 50 g /min
  • the outlet temperature under these conditions was about 80 0 C.
  • a free-flowable powder was obtained. This Example shows that a scale up to larger equipment is also possible and resulted in a powder having the same properties as a powder produced on a small lab scale.
  • Example 22 Measurement of temperature stability of powder obtained in Example 21 (SD TPGS).
  • the product of example 21 large scale production compound 1 SD TPGS
  • the product of example 21 was placed in an oven at 8O 0 C and kept at 8O 0 C for 4 weeks. No major changes with regard to the powder morphology were observed. Even after 4 weeks storage at 8O 0 C a free-flowable powder was still remaining. In contrast a physical mixture with the same composition was completely molten already after 1 hour storage at 8O 0 C in the same oven.
  • Example 23 Comparative bioavailability data for 4 different formulations of COMPOUND 1 in male beagle dogs.
  • the relative bio-availability in male beagle dogs of the composition according to the present invention was about 6 times higher as compared with the relative bio-availability of a tablet containing a micronized active compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur une composition solide thermostable contenant des micelles de dimension nanométrique ; les micelles contiennent une substance chimique faiblement soluble, telle qu'une substance biologiquement active, dissoute dans une matière auxiliaire, et sont noyées dans un support soluble dans l'eau. L'invention porte en outre sur un procédé de préparation d'une composition solide thermostable et sur un procédé de préparation de formes posologiques pharmaceutiques comprenant celle-ci.
EP07821558A 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques Withdrawn EP2083799A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07821558A EP2083799A1 (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85302306P 2006-10-20 2006-10-20
EP06122648 2006-10-20
EP07821558A EP2083799A1 (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques
PCT/EP2007/061194 WO2008046905A1 (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques

Publications (1)

Publication Number Publication Date
EP2083799A1 true EP2083799A1 (fr) 2009-08-05

Family

ID=38661928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07821558A Withdrawn EP2083799A1 (fr) 2006-10-20 2007-10-19 Nanoparticules micellaires de substances chimiques

Country Status (9)

Country Link
EP (1) EP2083799A1 (fr)
JP (1) JP5439182B2 (fr)
KR (1) KR101434334B1 (fr)
AU (1) AU2007312233B2 (fr)
CA (1) CA2666587C (fr)
EA (1) EA026213B1 (fr)
IL (1) IL197701A (fr)
NO (1) NO20091975L (fr)
WO (1) WO2008046905A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
US20150111246A1 (en) * 2012-04-24 2015-04-23 Astrazeneca Pharmaceuticals Lp Site-specific enzymatic modification of exendins and analogs thereof
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
FR3014317B1 (fr) * 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
EP3424493A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
EP3886910A4 (fr) * 2018-11-30 2022-07-27 Canopy Growth Corporation Compositions comprenant un cannabinoïde ou un composé dérivé du cannabis, méthodes de fabrication et d'utilisation
WO2021013262A1 (fr) * 2019-07-25 2021-01-28 北京盛诺基医药科技股份有限公司 Préparation nanomicellaire d'icaritine et son procédé de préparation et son application
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
JP2023504756A (ja) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド カンナビノイドを含む口腔用製品
US20230174493A1 (en) * 2020-03-24 2023-06-08 Inversago Pharma Inc. Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors
EP4373293A1 (fr) * 2021-07-22 2024-05-29 Nicoventures Trading Limited Compositions comprenant des constituants, des dérivés ou des extraits de cannabis
EP4373303A1 (fr) * 2021-07-22 2024-05-29 Nicoventures Trading Limited Compositions comprenant un constituant, un dérivé ou un extrait de cannabis
MX2024000930A (es) * 2021-07-22 2024-02-07 Nicoventures Trading Ltd Composiciones que comprenden un constituyente, derivado o extracto de cannabis.
US20240325414A1 (en) * 2021-07-22 2024-10-03 Nicoventures Trading Limited Constituent, derivative or extract of cannabis in a water soluble matrix
AU2023321655A1 (en) 2022-08-12 2025-02-13 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
IL157704A0 (en) * 2001-09-21 2004-03-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
KR100903760B1 (ko) * 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP4994039B2 (ja) * 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
WO2005053727A2 (fr) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Compositions pharmaceutiques pour agents peptidiques bioactifs
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP2008517976A (ja) * 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
ES2545589T3 (es) * 2005-04-08 2015-09-14 Abbott Laboratories Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico
KR20080042039A (ko) * 2005-04-18 2008-05-14 루비콘 리서치 피브이티. 엘티디. 생물학적으로 강화된 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DR CARLOTA DE OLIVEIRA ET AL: "Corresponding Author: Micellar solubilization of drugs", J PHARM PHARMACEUT SCI (WWW.CSPSCANADA.ORG), 8 July 2005 (2005-07-08), pages 147 - 163, XP055165728, Retrieved from the Internet <URL:http://www.ualberta.ca/~csps/JPPS8(2)/C.Rangel-Yagui/solubilization.pdf> [retrieved on 20150129] *

Also Published As

Publication number Publication date
JP2010506886A (ja) 2010-03-04
NO20091975L (no) 2009-07-09
IL197701A0 (en) 2009-12-24
CA2666587C (fr) 2015-12-22
IL197701A (en) 2014-12-31
KR20090077074A (ko) 2009-07-14
AU2007312233A1 (en) 2008-04-24
EA026213B1 (ru) 2017-03-31
KR101434334B1 (ko) 2014-08-28
CA2666587A1 (fr) 2008-04-24
EA200900572A1 (ru) 2009-10-30
WO2008046905A1 (fr) 2008-04-24
JP5439182B2 (ja) 2014-03-12
AU2007312233B2 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
CA2666587C (fr) Nanoparticules micellaires de substances chimiques
US7923026B2 (en) Embedded micellar nanoparticles
US12502357B2 (en) Formulations of enzalutamide
US20200330600A1 (en) Pharmaceutical composition
Sharma et al. Solid dispersion: A promising technique to enhance solubility of poorly water soluble drug
EP2146577A1 (fr) Formulations de ziprasidone
KR102490397B1 (ko) 두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
EP3254699A2 (fr) Dispersion solide contenant du dutastéride et composition la contenant
TWI392507B (zh) 包埋的膠束奈米顆粒
US20040001888A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
ES2663721T3 (es) Formulaciones de olmesartán
EP4045143B1 (fr) Système de vecteur de médicament autonanoémulsifiant liquide chargé de bosentan monohydraté et formulation de comprimé
CN109260207A (zh) 嘧啶二酮衍生物化合物的制剂
CN113081970A (zh) 一种环孢素固体分散体及其片剂制备方法
HK1138510A (en) Micellar nanoparticles of chemical substances
CN106822122B (zh) 一种替米沙坦和氨氯地平的口服药用组合物及其制备方法
Lalani et al. LIQUISOLID COMPACT APPROACH TO ENHANCE DISSOLUTION RATE OF POORLY SOLUBLE DRUGS: A RECENT RESEARCH REVIEW.
BR102016015553A2 (pt) Sistemas multiparticulados liquissólidos para administração oral, processo de obtenção dos mesmos e seus usos

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20090520

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT HEALTHCARE PRODUCTS B.V.

17Q First examination report despatched

Effective date: 20111215

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE B.V.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180904